Symbols / AGMB Stock $10.33 +5.41% AgomAb Therapeutics NV

Healthcare • Biotechnology • Belgium • NMS
AGMB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Tim Knotnerus MSc, Ph.D.
Exch · Country NMS · Belgium
Market Cap 508.73M
Enterprise Value 667.05M
Income -77.50M
Sales —
FCF (ttm) -24.37M
Book/sh -3.95
Cash/sh 2.37
Employees 62
Insider 10d —
IPO Feb 06, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.17
PEG —
P/S —
P/B -2.61
P/C —
EV/EBITDA -11.33
EV/Sales —
Quick Ratio 6.49
Current Ratio 6.52
Debt/Eq 0.96
LT Debt/Eq —
EPS (ttm) -1.48
EPS next Y -2.00
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -20.58%
ROE -39.22%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 49.25M
Shs Float 16.41M
Insider Own 5.90%
Instit Own 48.35%
Short Float 1.94%
Short Ratio 11.87
Short Interest 791.05K
52W High 17.45
vs 52W High -40.80%
52W Low 8.75
vs 52W Low 18.06%
Beta —
Impl. Vol. —
Rel Volume 0.70
Avg Volume 138.74K
Volume 97.03K
Target (mean) $32.00
Tgt Median $32.00
Tgt Low $28.00
Tgt High $36.00
# Analysts 3
Recom None
Prev Close $9.80
Price $10.33
Change 5.41%
About

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$32.00
Mean price target
2. Current target
$10.33
Latest analyst target
3. DCF / Fair value
$-8.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.33
Low
$28.00
High
$36.00
Mean
$32.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-03 init Leerink Partners — → Outperform $36
2026-03-03 init JP Morgan — → Overweight $32
2026-03-03 init Morgan Stanley — → Overweight $28
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
59.27
+23.44%
48.02
+53.96%
31.19
+37.80%
22.63
Research And Development
48.88
+24.34%
39.31
+49.41%
26.31
+35.48%
19.42
Selling General And Administration
12.57
+28.00%
9.82
+63.78%
6.00
+33.56%
4.49
General And Administrative Expense
12.57
+28.00%
9.82
+63.78%
6.00
+33.56%
4.49
Salaries And Wages
9.11
+78.43%
5.10
+46.67%
3.48
+26.32%
2.75
Other Gand A
3.25
-28.97%
4.58
+95.85%
2.34
+45.01%
1.61
Other Operating Expenses
-1.88
-83.69%
-1.02
-15.58%
-0.89
+0.00%
-0.89
Total Expenses
59.27
+23.44%
48.02
+53.96%
31.19
+37.80%
22.63
Operating Income
-59.27
-23.44%
-48.02
-53.96%
-31.19
-37.80%
-22.63
Total Operating Income As Reported
-59.27
-23.44%
-48.02
-53.96%
-31.19
-37.80%
-22.63
EBITDA
-62.27
-35.70%
-45.88
-286.27%
-11.88
-10.63%
-10.74
Normalized EBITDA
-62.31
-36.48%
-45.65
-284.10%
-11.89
-11.58%
-10.65
Reconciled Depreciation
0.22
-29.58%
0.31
+214.14%
0.10
+330.43%
0.02
EBIT
-62.49
-35.26%
-46.20
-285.67%
-11.98
-11.31%
-10.76
Total Unusual Items
0.04
+116.88%
-0.23
-3400.00%
0.01
+108.14%
-0.09
Total Unusual Items Excluding Goodwill
0.04
+116.88%
-0.23
-3400.00%
0.01
+108.14%
-0.09
Net Income
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Pretax Income
-62.55
-35.20%
-46.26
-285.24%
-12.01
-11.13%
-10.81
Net Non Operating Interest Income Expense
1.55
+35.50%
1.14
+443.33%
0.21
+740.00%
0.03
Interest Expense Non Operating
0.06
-10.45%
0.07
+116.13%
0.03
-31.11%
0.04
Net Interest Income
1.55
+35.50%
1.14
+443.33%
0.21
+740.00%
0.03
Interest Expense
0.06
-10.45%
0.07
+116.13%
0.03
-31.11%
0.04
Interest Income Non Operating
1.61
+32.10%
1.22
+397.14%
0.24
+245.07%
0.07
Interest Income
1.61
+32.10%
1.22
+397.14%
0.24
+245.07%
0.07
Other Income Expense
-4.82
-880.88%
0.62
-96.75%
18.97
+60.73%
11.80
Other Non Operating Income Expenses
-4.86
-672.76%
0.85
-95.53%
18.96
+59.51%
11.89
Gain On Sale Of Security
0.04
+116.88%
-0.23
-3400.00%
0.01
+108.14%
-0.09
Tax Provision
0.00
-100.00%
0.00
+100.65%
-0.62
+76.76%
-2.66
Tax Rate For Calcs
0.00
-100.00%
0.00
+400.00%
0.00
-87.18%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.06
-16600.00%
0.00
+101.04%
-0.03
Net Income Including Noncontrolling Interests
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Net Income From Continuing Operation Net Minority Interest
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Net Income From Continuing And Discontinued Operation
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Net Income Continuous Operations
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Normalized Income
-62.59
-35.78%
-46.09
-304.45%
-11.40
-40.88%
-8.09
Net Income Common Stockholders
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Diluted EPS
—
-1.28
-306.21%
-0.31
-39.89%
-0.22
Basic EPS
—
-1.28
-306.21%
-0.31
-39.89%
-0.22
Basic Average Shares
—
36.24
+0.00%
36.24
+0.00%
36.24
Diluted Average Shares
—
36.24
+0.00%
36.24
+0.00%
36.24
Diluted NI Availto Com Stockholders
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Depreciation Amortization Depletion Income Statement
0.22
-29.58%
0.31
+214.14%
0.10
+330.43%
0.02
Depreciation And Amortization In Income Statement
0.22
-29.58%
0.31
+214.14%
0.10
+330.43%
0.02
Other Taxes
-0.51
-28.64%
-0.40
-20.24%
-0.33
+20.05%
-0.41
Rent And Landing Fees
0.21
+54.01%
0.14
-23.03%
0.18
+45.90%
0.12
Rent Expense Supplemental
0.21
+54.01%
0.14
-23.03%
0.18
+45.90%
0.12
Total Other Finance Cost
0.00
-70.00%
0.01
+150.00%
0.00
+300.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
153.71
-25.51%
206.36
+20.49%
171.26
+69.57%
101.00
Current Assets
121.24
-30.26%
173.84
+24.64%
139.47
+96.21%
71.08
Cash Cash Equivalents And Short Term Investments
116.51
-32.05%
171.46
+40.08%
122.40
+80.88%
67.67
Cash And Cash Equivalents
86.42
-49.60%
171.46
+40.08%
122.40
+342.36%
27.67
Cash Equivalents
0.00
-100.00%
145.00
0.00
—
Cash Financial
86.42
+226.61%
26.46
-78.38%
122.40
+342.36%
27.67
Other Short Term Investments
30.10
0.00
0.00
-100.00%
40.00
Receivables
4.08
+92.78%
2.12
-87.50%
16.95
+409.04%
3.33
Other Receivables
3.87
+129.95%
1.68
-89.89%
16.65
+433.82%
3.12
Taxes Receivable
0.20
-47.51%
0.38
+159.18%
0.15
+101.37%
0.07
Current Deferred Assets
0.64
+138.95%
0.27
+122.50%
0.12
+41.18%
0.09
Other Current Assets
—
—
0.00
—
Total Non Current Assets
32.47
-0.14%
32.51
+2.29%
31.79
+6.27%
29.91
Net PPE
1.59
-20.38%
1.99
+24.03%
1.61
+2490.32%
0.06
Gross PPE
2.41
-0.41%
2.42
+39.93%
1.73
+1932.94%
0.09
Accumulated Depreciation
-0.82
-92.96%
-0.43
-249.18%
-0.12
-430.43%
-0.02
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
1.35
+2.35%
1.32
-6.25%
1.41
+2325.86%
0.06
Machinery Furniture Equipment
0.69
-5.62%
0.73
+127.41%
0.32
+1088.89%
0.03
Other Properties
0.01
+0.00%
0.01
—
—
Leases
0.36
+0.00%
0.36
0.00
—
Goodwill And Other Intangible Assets
28.72
+0.00%
28.72
+0.00%
28.72
+0.00%
28.72
Goodwill
8.61
+0.00%
8.61
+0.00%
8.61
+0.00%
8.61
Other Intangible Assets
20.11
+0.00%
20.11
+0.00%
20.11
+0.00%
20.11
Investments And Advances
0.01
-8.33%
0.01
-14.29%
0.01
+0.00%
0.01
Non Current Accounts Receivable
2.15
+20.31%
1.79
+23.75%
1.44
+29.86%
1.11
Other Non Current Assets
—
—
-0.00
—
Total Liabilities Net Minority Interest
22.80
+24.77%
18.28
-7.80%
19.82
-42.95%
34.75
Current Liabilities
18.59
+103.69%
9.13
-16.16%
10.88
-63.37%
29.72
Payables And Accrued Expenses
10.35
+28.55%
8.05
-2.94%
8.30
+80.54%
4.59
Payables
7.89
+28.80%
6.13
-12.84%
7.03
+77.44%
3.96
Accounts Payable
7.63
+28.16%
5.95
-12.86%
6.83
+75.31%
3.90
Current Accrued Expenses
2.46
+27.77%
1.92
+52.14%
1.26
+100.00%
0.63
Total Tax Payable
0.27
+50.28%
0.18
-12.38%
0.20
+201.49%
0.07
Current Debt And Capital Lease Obligation
0.25
-8.79%
0.27
+50.83%
0.18
+596.15%
0.03
Current Capital Lease Obligation
0.25
-8.79%
0.27
+50.83%
0.18
+596.15%
0.03
Current Deferred Liabilities
1.46
+82.40%
0.80
-32.18%
1.18
-33.50%
1.78
Current Deferred Revenue
1.46
+82.40%
0.80
-32.18%
1.18
-33.50%
1.78
Other Current Liabilities
6.53
—
1.23
-94.74%
23.32
Total Non Current Liabilities Net Minority Interest
4.21
-53.94%
9.15
+2.37%
8.94
+77.68%
5.03
Long Term Debt And Capital Lease Obligation
1.00
-20.99%
1.27
-11.61%
1.44
+3897.22%
0.04
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
1.00
-20.99%
1.27
-11.61%
1.44
+3897.22%
0.04
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.62
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
0.62
Other Non Current Liabilities
3.21
-59.26%
7.88
+5.05%
7.50
+71.51%
4.37
Stockholders Equity
130.90
-30.40%
188.08
+24.20%
151.44
+128.59%
66.25
Common Stock Equity
130.90
-30.40%
188.08
+24.20%
151.44
+128.59%
66.25
Capital Stock
223.07
+0.00%
223.07
+27.68%
174.71
+58.24%
110.41
Common Stock
223.07
+0.00%
223.07
+27.68%
174.71
+58.24%
110.41
Share Issued
48.74
+0.00%
48.74
+0.00%
48.74
+0.00%
48.74
Ordinary Shares Number
48.74
+0.00%
48.74
+0.00%
48.74
+0.00%
48.74
Additional Paid In Capital
76.63
+0.00%
76.63
+78.47%
42.94
+247.18%
12.37
Retained Earnings
-181.71
-52.47%
-119.18
-63.64%
-72.83
-18.54%
-61.44
Gains Losses Not Affecting Retained Earnings
-0.97
-0.10%
-0.97
-15.41%
-0.84
-117.97%
-0.38
Other Equity Adjustments
-0.97
-0.10%
-0.97
-15.41%
-0.84
-117.97%
-0.38
Total Equity Gross Minority Interest
130.90
-30.40%
188.08
+24.20%
151.44
+128.59%
66.25
Total Capitalization
130.90
-30.40%
188.08
+24.20%
151.44
+128.59%
66.25
Working Capital
102.65
-37.68%
164.72
+28.10%
128.59
+210.83%
41.37
Invested Capital
130.90
-30.40%
188.08
+24.20%
151.44
+128.59%
66.25
Total Debt
1.25
-18.83%
1.54
-4.63%
1.62
+2512.90%
0.06
Capital Lease Obligations
1.25
-18.83%
1.54
-4.63%
1.62
+2512.90%
0.06
Net Tangible Assets
102.18
-35.88%
159.36
+29.86%
122.71
+227.01%
37.53
Tangible Book Value
102.18
-35.88%
159.36
+29.86%
122.71
+227.01%
37.53
Available For Sale Securities
0.01
-8.33%
0.01
-14.29%
0.01
+0.00%
0.01
Investmentin Financial Assets
0.01
-8.33%
0.01
-14.29%
0.01
+0.00%
0.01
Notes Receivable
0.01
-72.73%
0.06
-64.29%
0.15
+11.59%
0.14
Other Equity Interest
13.88
+62.84%
8.52
+14.34%
7.45
+40.81%
5.29
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-51.74
-10.49%
-46.83
-90.42%
-24.59
-29.66%
-18.97
Cash Flow From Continuing Operating Activities
-51.74
-10.49%
-46.83
-90.42%
-24.59
-29.66%
-18.97
Net Income From Continuing Operations
-62.55
-35.19%
-46.27
-306.21%
-11.39
-39.89%
-8.14
Depreciation Amortization Depletion
0.22
-29.58%
0.31
+214.14%
0.10
+330.43%
0.02
Depreciation
—
0.31
+214.14%
0.10
+330.43%
0.02
Amortization Cash Flow
—
0.00
0.00
0.00
Depreciation And Amortization
0.22
-29.58%
0.31
+214.14%
0.10
+330.43%
0.02
Amortization Of Intangibles
—
0.00
0.00
0.00
Other Non Cash Items
-1.54
-35.53%
-1.14
-425.35%
-0.22
-455.74%
0.06
Stock Based Compensation
5.36
+400.00%
1.07
-50.39%
2.16
-2.26%
2.21
Deferred Tax
0.00
-100.00%
0.00
+100.65%
-0.62
+76.76%
-2.66
Deferred Income Tax
0.00
-100.00%
0.00
+100.65%
-0.62
+76.76%
-2.66
Operating Gains Losses
0.06
-75.32%
0.23
—
—
Unrealized Gain Loss On Investment Securities
4.76
+661.44%
-0.85
+95.53%
-18.96
-59.51%
-11.89
Net Foreign Currency Exchange Gain Loss
0.06
-75.32%
0.23
0.00
—
Change In Working Capital
0.41
+131.67%
-1.28
-131.13%
4.12
+192.26%
1.41
Change In Prepaid Assets
—
-0.40
+31.90%
-0.58
-140.08%
1.45
Change In Payables And Accrued Expense
2.36
+1125.65%
-0.23
-106.24%
3.69
+24.91%
2.95
Change In Payable
2.36
+1125.65%
-0.23
-106.24%
3.69
+24.91%
2.95
Change In Other Working Capital
0.75
+289.11%
-0.40
+31.90%
-0.58
-140.08%
1.45
Change In Other Current Assets
-2.70
-310.96%
-0.66
-164.92%
1.01
+133.86%
-2.99
Investing Cash Flow
-33.00
-4789.48%
-0.68
-101.69%
40.00
+189.71%
-44.59
Cash Flow From Continuing Investing Activities
-33.00
-4789.48%
-0.68
-101.69%
40.00
+189.71%
-44.59
Net PPE Purchase And Sale
-0.00
+99.41%
-0.68
0.00
—
Purchase Of PPE
-0.00
+99.41%
-0.68
0.00
—
Capital Expenditure
-0.00
+99.41%
-0.68
—
—
Net Investment Purchase And Sale
-30.00
0.00
-100.00%
40.00
+200.00%
-40.00
Purchase Of Investment
-30.00
—
—
—
Sale Of Investment
—
0.00
-100.00%
40.00
—
Net Business Purchase And Sale
-3.00
0.00
0.00
+100.00%
-4.59
Purchase Of Business
-3.00
0.00
0.00
+100.00%
-4.59
Financing Cash Flow
-0.34
-100.35%
96.76
+21.98%
79.32
+110.79%
37.63
Cash Flow From Continuing Financing Activities
-0.34
-100.35%
96.76
+21.98%
79.32
+110.79%
37.63
Net Issuance Payments Of Debt
-0.34
-107.36%
-0.16
-63.00%
-0.10
+86.05%
-0.72
Repayment Of Debt
-0.34
-107.36%
-0.16
-63.00%
-0.10
+86.05%
-0.72
Long Term Debt Payments
-0.34
-107.36%
-0.16
-63.00%
-0.10
+86.05%
-0.72
Net Long Term Debt Issuance
-0.34
-107.36%
-0.16
-63.00%
-0.10
+86.05%
-0.72
Net Common Stock Issuance
0.00
-100.00%
97.06
+21.51%
79.87
+108.08%
38.38
Net Other Financing Charges
—
-0.13
+70.92%
-0.45
-1141.67%
-0.04
Changes In Cash
-85.09
-272.72%
49.26
-48.00%
94.73
+465.46%
-25.92
Effect Of Exchange Rate Changes
0.04
+122.06%
-0.20
0.00
0.00
Beginning Cash Position
171.46
+40.08%
122.40
+342.36%
27.67
-48.37%
53.59
End Cash Position
86.42
-49.60%
171.46
+40.08%
122.40
+342.36%
27.67
Free Cash Flow
-51.74
-8.93%
-47.50
-93.16%
-24.59
-29.66%
-18.97
Common Stock Issuance
0.00
-100.00%
97.06
+21.51%
79.87
+108.08%
38.38
Interest Paid CFO
-0.07
-590.00%
-0.01
+50.00%
-0.02
+54.55%
-0.04
Interest Received CFO
1.62
+46.65%
1.11
+351.43%
0.24
+240.28%
0.07
Issuance Of Capital Stock
0.00
-100.00%
97.06
+21.51%
79.87
+108.08%
38.38
Taxes Refund Paid
0.00
+100.00%
-0.00
-33.33%
-0.00
-50.00%
-0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category